微信小陈
微信小章| 产品名称： | CEM/C2 |
|---|---|
| 商品货号： | TS212396 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Cell Type： | T lymphoblast |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | acute lymphoblastic leukemia |
| Age： | 4 years |
| Gender： | female |
| Ethnicity： | Caucasian |
| Applications： | The cell line was selected and subcloned in 1991 for resistance to CPT. |
| Storage Conditions： | liquid nitrogen vapor temperature |
| Derivation： | CEM/C2 is a camptothecin (CPT) resistant derivative of the human T cell leukemia cell line CCRF-CEM (see ATCC CCL-119). |
| Comments： | The cells are approximately 970-fold less sensitive to CPT than the parental CEM cells. CEM/C2 cells exhibit cross resistance to both the water soluble (topotecan) and water insoluble (9-amino-CPT and 10,11-methylenedioxy-CPT) analogs of CPT. Resistance to CPT is stable for up to six months. CEM/C2 cells are also cross resistant to etoposide, dactinomycin, bleomycin, mitoxantrone, 4-(9-acridinylamino)methanesulfon-m-anisidide, and the anthracyclines daunorubicin and doxorubicin but retain sensitivity to the Vinca alkaloid vincristine. CEM/C2 cells display atypical multidrug resistance (MDR), altered topoisomerase I catalytic activity and a unique topoisomerase I mutation (Asn722Ser). |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 x 105 viable cells/mL. Maintain cultures at a cell concentration between 2 x 105 and 2 x 106 cells/mL.
Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Freeze medium: Complete growth medium 95%; DMSO, 5%. Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 11 D13S317: 11,12 D16S539: 10,13 D5S818: 13 D7S820: 9,8.3 THO1: 6,7 TPOX: 8 vWA: 17,19 |
| Population Doubling Time： | 30 hrs |
| Name of Depositor： | WG Harker |
| Deposited As： | Homo sapiens |
| References： | Kapoor R, et al. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res. 7: 83-95, 1995. PubMed: 7579731 Fujimori A, et al. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 55: 1339-1346, 1995. PubMed: 7882333 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |